The global oncology market was valued at US$ 203.42 billion in 2022 and is expected to reach over US$ 470.61 billion by 2032, poised to grow at a noteworthy CAGR of 8.8% from 2023 to 2032.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
Key Takeaway:
Some sales insight revealing the strong growth of oncology during the past few years are listed below:
Growth Factors
The rising oncology burden across the globe owing to the increased consumption of alcohol and tobacco is driving the growth of the global oncology market. The International Agency for Research on Cancer (IARC), in its report GLOBOCAN, has stated that approximately 19.3 million new cancer cases and about 10 million deaths related to cancer were recorded in 2020, across the globe. The IARC has estimated that the new cancer cases are expected to rise by 47% all over the globe from 2020 to 2040. Therefore, the growing prevalence of cancer is expected to foster the adoption of the oncology diagnostics and oncology treatment across the globe, thereby boosting the growth of the global oncology market. Furthermore, the rising initiatives of government and various non-profit organizations in spreading the awareness regarding the prevention of cancer is expected to fuel the growth of the market. For instance, World Health Organization’s Global Action Plan for Prevention and Control of Non-Communicable Diseases, aims at decreasing the premature death due to cancer, cardiovascular diseases, chronic respiratory diseases, and diabetes by around 25% by the year 2025. The rising prevalence of the various chronic diseases has augmented the demand for the early diagnostics and treatment of cancer across the globe.
The rising investments and developments in the biopharmaceutical industry is encouraging the development of various innovative drugs and therapeutics, which fosters the demand for the oncology treatment and oncology diagnostics. The growing awareness among the population regarding the availability of various drugs and diagnostics related to oncology is expected to drive the global oncology market growth. The oncology therapeutics alone accounts for around 20% of the global sales of the pharmaceuticals. Therefore, the rising importance and higher potential of profit is attracting the market players to invest in the oncology market.
Scope of the Oncology Market
| Report Coverage | Details |
| Market Size in 2023 | US$ 220.30 Billion |
| Market Size by 2032 | US$ 470.61 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 8.8% |
| Largest Market | North America |
| Fastest Growing Market | Europe |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Cancer Diagnostics & Treatment, Indication, Region |
| Companies Mentioned | Aegerion Pharmaceuticals Inc., Abbvie Inc., Ability Pharma, Acadia Pharmaceuticals Inc., Amgen Inc., Takeda Oncology, Aslan Pharmaceuticals Ltd., Aspen Pharmacare Holdings Limited., Astrazeneca, Athenex, Inc. |
Cancer Diagnostics & Treatment Insights
The cancer treatment segment dominated the oncology market in 2022, garnering a market share of around 56%. This is attributable to the increased adoption of the traditional chemotherapy and immunotherapy for the treatment of cancer across the globe. People are now increasingly adopting the targeted therapy and immunotherapy for the treatment as they are more convenient, effective, and has low side-effects as compared to that of the traditional chemotherapy. The low toxicity and the ability of the targeted therapy to specifically target the cancer cells without harming the normal cells is boosting the growth of the cancer treatment segment significantly. Moreover, the rising awareness among the population regarding the benefits of the targeted therapy, hormonal therapy, and the immunotherapy is fueling the demand for these cancer treatments among the global cancer patients.
On the other hand, the cancer diagnostics segment is estimated to be the most opportunistic segment. The increased awareness among the population regarding the cancer disease is augmenting the demand for the cancer diagnostics across the globe. The rising preferences of the people to detect cancer as early as possible is propelling the growth of the cancer diagnostics segment. The availability of various non-invasive and convenient diagnostic tools is expected to drive the growth of this segment during the forecast period.
Indication Insights
Based on the indication, the lungs cancer segment dominated the market in 2022, owing to the increased cases of lungs cancer across the globe. According to the International Agency for Research on Cancer, around 1.8 million deaths were recorded due to lungs cancer in 2020. Lungs cancer is the most diagnosed type of cancer among the global population and it accounts for around 18% of the cancer deaths all over the globe. It is recognized as the leading cause of cancer deaths. The increased prevalence of smoking around the globe is a major factor that boosts the growth of this segment.
Breast cancer, on the other hand, is anticipated to be the fastest-growing market during the forecast period. This is due to the growing prevalence of the breast cancer among the female population. As per the IARC, breast cancer has surpassed the lungs cancer as the most diagnosed type of cancer in 2020. Around 2.3 million or 11.7% of the new cancer cases reported as the breast cancer in 2020.
Regional Insights
North America dominated the global oncology market in 2021. This can be attributed to the increased prevalence of cancer in the major market like US. According to the American Cancer Society, over 1.8 million new cancer cases and 606,520 deaths were reported in the US in 2020. The most prominent type of cancer in North America includes lungs cancer, colorectal cancer, breast cancer, and the prostate cancer. The North America oncology market is expected to sustain its significance owing to the presence of developed healthcare infrastructure and the increased healthcare expenditure. The increased adoption of the oncology treatments in US has resulted in a decline of cancer deaths by around 29% since 1991.
Europe is anticipated to be the most opportunistic market during the forecast period. This is attributable to the rising technological advancements in the diagnostics of various cancers. Moreover, the rising prevalence of cancer across Europe and growing number of cancer deaths is expected to foster the growth of the Europe oncology market in the forthcoming years.According to the European Commission, approximately 2.7 million new cancer cases and about 1.3 million cancer deaths were recorded in 2020.
Key Developments
The various developmental strategies such as mergers, partnerships, acquisitions, and collaborations significantly contributes towards the market growth. The major players in the market are collaborating for the research and development purposes and heavily investing in the areas of oncology for the development of the innovative oncology diagnostics and treatment therapies. These market players are striving to exploit the prevailing market opportunities and focusing on gaining market share by introducing innovative oncology solutions.
Some of the prominent players in the global oncology market include:
Segments Covered in the Report
By Cancer Diagnostics & Treatment
By Indication
By End-use
By Geography
PROCEED TO BUY :
ASK FOR SAMPLE
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
